Isolinderalactone

Isolinderalactone 是一种具有抗癌、抗炎和神经保护作用的倍半萜,它抑制 VEGF 表达和 VEGFR2 酪氨酸磷酸化,降低 U-87 胶质母细胞瘤 (GBM) 细胞和结直肠癌 (CRC) 细胞的存活率并诱导其凋亡 (apoptosis),在结直肠癌 (CRC) 细胞中诱导 G2/M 期细胞周期停滞、活性氧 (ROS) 生成和 pJNK/p38 MAPK 激活,在 RAW264.7 巨噬细胞中阻断 LPS (MS-X54539) 诱导的 NF-κB 活化并激活 Nrf2-HMOX1 信号通路,改善 APP/PS1 小鼠的认知功能障碍,可用于研究胶质母细胞瘤 (GBM)、结直肠癌、阿尔茨海默病和急性肺损伤。
产品编号: MS-T30797 纯度: 98.79% CAS No.: 957-66-4 分子式: C15H16O3 分子量: 244.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Isolinderalactone 是一种具有抗癌、抗炎和神经保护作用的倍半萜,它抑制 VEGF 表达和 VEGFR2 酪氨酸磷酸化,降低 U-87 胶质母细胞瘤 (GBM) 细胞和结直肠癌 (CRC) 细胞的存活率并诱导其凋亡 (apoptosis),在结直肠癌 (CRC) 细胞中诱导 G2/M 期细胞周期停滞、活性氧 (ROS) 生成和 pJNK/p38 MAPK 激活,在 RAW264.7 巨噬细胞中阻断 LPS (MS-X54539) 诱导的 NF-κB 活化并激活 Nrf2-HMOX1 信号通路,改善 APP/PS1 小鼠的认知功能障碍,可用于研究胶质母细胞瘤 (GBM)、结直肠癌、阿尔茨海默病和急性肺损伤。

生物实验数据

生物活性 Isolinderalactone is a sesquiterpene with anticancer, anti-inflammatory, and neuroprotective effects that inhibits VEGF expression and VEGFR2 tyrosine phosphorylation, reduces viability and induces apoptosis (apoptosis) in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells, induces G2/M cell cycle arrest, reactive oxygen species (ROS) generation, and pJNK/p38 MAPK activation in colorectal cancer (CRC) cells, blocks LPS (MS-X54539)-induced NF-κB activation while activating the Nrf2-HMOX1 signaling pathway in RAW264.7 macrophages, ameliorates cognitive impairment in APP/PS1 mice, and can be used for research on glioblastoma (GBM), colorectal cancer, Alzheimer's disease, and acute lung injury.
IC50 & Target iNOS:0.30 uM
体外研究
(In Vitro)

Isolinderalactone (0.5-2.5 μg/mL, 24-72 h) 抑制 U-87 胶质母细胞瘤细胞生长。
Isolinderalactone (0.5-2.5 μg/mL, 48 h) 通过降低 BCL-2、survivin 和 XIAP 表达,增加 cleaved caspase-3,并诱导 DNA 断裂,激活 U-87 GBM 细胞的凋亡途径,从而促进细胞凋亡。
Isolinderalactone (0.5-2 μg/mL, 48 h) 抑制 U-87 GBM 细胞中 VEGF 表达,并抑制人脑微血管内皮细胞 (HBMECs) 的 VEGF 诱导血管生成。
Isolinderalactone (2 μg/mL, 8 days) 在三维微流控芯片中抑制血管生成萌发。
Isolinderalactone (2.5-5 μg/mL, 48 h) 降低 U-87 细胞中 HIF 表达和活性以及 HBMECs 中 VEGFR2 激活。
Isolinderalactone (0-9 μM, 24-48 h) 抑制结直肠癌细胞 (HCT116, HCT116-OxR, HT29, HT29-OxR) 的增殖和集落形成。
Isolinderalactone (0-9 μM, 48 h) 在结直肠癌细胞中诱导凋亡、G2/M 期细胞周期停滞、活性氧 (ROS) 生成和内质网应激。
Isolinderalactone (0-9 μM, 48 h) 在结直肠癌细胞中诱导凋亡,通过线粒体和 caspase 依赖途径,可能通过调节 JNK/p38 MAPK 激活,其中 ROS 发挥关键作用。
Isolinderalactone (10 μM, 2-27 h) 减轻 Aβ1-42 诱导的细胞损伤并降低 PC12 细胞中的神经毒性。
Isolinderalactone (10 μM, 27 h) 通过抑制 JNK 减少 PC12 细胞中的神经元细胞损伤。
Isolinderalactone (0.5-10 μM, 19 h) 在 RAW264.7 细胞、MH-S 细胞和骨髓源性巨噬细胞 (BMDMs) 中抑制 LPS 或 TNF-α 诱导的炎症反应。
Isolinderalactone (1-10 μM, 13 h) 在 LPS 刺激的 RAW264.7 巨噬细胞中抑制促炎酶和细胞因子的 mRNA 表达。
Isolinderalactone (1-10 μM, 2-9 h) 在 RAW264.7 巨噬细胞中阻断 LPS 诱导的 NF-κB 活化,同时激活 Nrf2-HMOX1 通路。

Cell Viability Assay

Cell Line: U-87 GBM cells and HBMECs
Concentration: 0.5, 1, 2, 2.5 μg/mL
Incubation Time: 24, 48, 72 h
Result: Inhibited cell viability in a dose-dependent manner.
Decreased VEGF-induced HBMEC proliferation in a dose-dependent manner.

Western Blot Analysis

Cell Line: U-87 GBM cells and HBMECs
Concentration: 0.5, 1, 2.5,5 μg/mL
Incubation Time: 48 h
Result: Decreased BCL-2, survivin, and XIAP expression.
Increased the level of cleaved caspase-3 and cleaved PARP.
Decreased the expression of the potent angiogenic factor, VEGF.
Decreased HIF expression and activity in U-87 cells.
Reduced phosphorylation of VEGFR2 in HBMECs.

Immunofluorescence

Cell Line: U-87 GBM cells
Concentration: 2.5 μg/mL
Incubation Time: 48 h
Result: Showed predominantly bright γ-H2AX nuclear staining.

Cell Viability Assay

Cell Line: HCT116, HCT116-OxR, HT29, and HT29-OxR cells
Concentration: 3, 6, 9 μM
Incubation Time: 24, 48 h
Result: Suppressed colorectal cancer cells proliferation with IC50 values of 8.05 μM (HCT116), 5.13 μM (HCT116-OxR), 10.38 μM (HT29) and 9.46 μM (HT29-OxR).

Cell Cycle Analysis

Cell Line: HCT116, HCT116-OxR, HT29, and HT29-OxR cells
Concentration: 3, 6, 9 μM
Incubation Time: 48 h
Result: Contributed to G2/M phase cell cycle arrest.

Western Blot Analysis

Cell Line: HCT116, HCT116-OxR, HT29, and HT29-OxR cells
Concentration: 3, 6, 9 μM
Incubation Time: 48 h
Result: Increased the expression levels of ER stress related proteins (GRP78, CHOP, DR4, and DR5).
Activated JNK/p38 MAPK.
Increased the levels of pro-apoptotic proteins (Bim and Bax), apaf-1, and cleaved (c)-PARP.
Decreased expression levels of anti-apoptotic proteins (Mcl-1, Bid, Bcl-xL and Bcl-2), mitochondrial cyto c and caspase 3 in a dose-dependent manner.

Western Blot Analysis

Cell Line: Aβ1-42-induced PC12 cells
Concentration: 10 μM
Incubation Time: 27 h
Result: Decreased Bax expression and intracellular levels of caspase-3 activation and increased Bcl2 levels.
Decreased the level of p-JNK, but had no significant effect on ERK and P38MAPK.

Real Time qPCR

Cell Line: LPS-exposed RAW264.7 macrophages
Concentration: 1, 10 μM
Incubation Time: 13 h
Result: Decreased the mRNA levels of iNOS, COX2, IL-1β, IL-6, and TNF-α.

Western Blot Analysis

Cell Line: LPS-exposed RAW264.7 macrophages
Concentration: 1, 5, 10 μM
Incubation Time: 2, 9 h
Result: Down-regulated LPS-induced phosphorylation of IKKα/β and the level of NF-κB p65.
Increased the protein level of Nrf2 protein in the cytoplasmic fraction and nuclear fraction.
体内研究
(In Vivo)

Isolinderalactone (1-5 mg/kg,腹腔注射,每隔一天一次,共 12 天) 抑制人 GBM 异种移植小鼠模型中的肿瘤生长。
Isolinderalactone (2.5-5 mg/kg,腹腔注射,每隔一天一次,共 16 天) 减少人 GBM 异种移植模型中的肿瘤生长和血管生成。
Isolinderalactone (5 mg/kg,腹腔注射,每天一次,共 6 天) 在小鼠体内 Matrigel 实验中抑制 VEGF 介导的血管生成。
Isolinderalactone (1-10 mg/kg,腹腔注射,每天一次,共 30 天) 改善 APP/PS1 小鼠的学习和记忆缺陷。
Isolinderalactone (2.5-10 mg/kg,腹腔注射,每日一次,持续 5 天) 可减轻 LPS 诱导的小鼠肺部炎症损伤。

Animal Model: U-87 GBM cells (3 × 106 cells/100 μL of serum-free DMEM) were subcutaneously implanted into the right flank of the BALB/C nude mice
Dosage: 1, 2.5, 5 mg/kg
Administration: i.p., every other day for 12 days
Result: Reduced tumor volume and weight Showed no differences on body weight.
Increased cleaved caspase-3 fluorescence.
Showed a significantly higher number of TUNEL-positive cells.
Animal Model: U-87 GBM cells (3 × 106 cells/100 μL of serum-free DMEM) were subcutaneously implanted into the right flank of the BALB/C nude mice
Dosage: 2.5, 5 mg/kg
Administration: i.p., every other day for 16 days
Result: Decreased tumor volume and suppressed tumor progression.
Inhibited tumor angiogenesis.
Reduced VEGF immunoreactivity.
Animal Model: C57BL/6 mice (6-week-old, male)
Dosage: 5 mg/kg
Administration: i.p. daily for 6 days
Result: Decreased hemoglobin concentration and CD31 staining.
Inhibited VEGF-induced new vessel formation in vivo.
Animal Model: 10-month-old APP/PS1 transgenic mice
Dosage: 1, 10 mg/kg
Administration: i.p. daily for 30 days
Result: Enhanced the exploration of the novel object by the mice.
Ameliorated learning and memory deficits in APP/PS1mice.
Reduced the level of APP/β-amyloid.
Increased the levels of synapse-associated proteins, including PSD95 and Map2.
Reduced neuronal apoptosis in the cortex and hippocampus.
Increased the SOD content and decreased MDA levels in the hippocampus.
Increased Bcl2 levels, decreased Bax, p-JNK expression, and decreased caspase-3 activation.
Animal Model: Male Institute of Cancer Research (ICR) mice (SPF grade, 20-22 g, 6 weeks old) injected with LPS (15 mg/kg)
Dosage: 2.5-10 mg/kg
Administration: i.p., daily for 5 days
Result: Improved the lung injury scores.
Reduced the MPO activity in LPS-exposed lung tissue.
Reduced the levels of PGE2, IL-1β, IL-6, and TNF-α.
性状 固体
颜色 White to off-white

化学信息

分子量 244.29
分子式 C15H16O3
CAS No. 957-66-4

储存&溶解度

体内实验配方
10% DMSO+90% Corn Oil: 2 mg/mL (8.19 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (204.67 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.0935 mL20.4675 mL40.9350 mL102.3374 mL
5 mM0.8187 mL4.0935 mL8.1870 mL20.4675 mL
10 mM0.4093 mL2.0467 mL4.0935 mL10.2337 mL
15 mM0.2729 mL1.3645 mL2.7290 mL6.8225 mL
20 mM0.2047 mL1.0234 mL2.0467 mL5.1169 mL
25 mM0.1637 mL0.8187 mL1.6374 mL4.0935 mL
30 mM0.1364 mL0.6822 mL1.3645 mL3.4112 mL
40 mM0.1023 mL0.5117 mL1.0234 mL2.5584 mL
50 mM0.0819 mL0.4093 mL0.8187 mL2.0467 mL
60 mM0.0682 mL0.3411 mL0.6822 mL1.7056 mL
80 mM0.0512 mL0.2558 mL0.5117 mL1.2792 mL
100 mM0.0409 mL0.2047 mL0.4093 mL1.0234 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Isolinderalactone 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础